Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Private pain management company TheraQuest Biosciences has unveiled positive new results from a trial of its opioid pain drug, TQ-1015.
Subscribe to our email newsletter
The study evaluated the effects of TQ-1015 in inflammatory pain against mechanical allodynia and thermal hyperalgesia and compared its potency with morphine. The results were presented at the American Pain Society Annual Scientific Meeting in Boston, Massachusetts.
Dr Michael Ossipov, associate professor in the department of pharmacology at the University of Arizona College of Medicine, stated, “TQ-1015 produced dose-dependent reversal of tactile hyperesthesia and thermal hyperalgesia. The potency of TQ-1015 remained constant over the time-course of the study.”
“Importantly,” he continued, “TQ-1015 retained its antinociceptive potency in the presence of inflammation. These results indicate that TQ-1015 is active against increased pain states associated with inflammation. It is consistently more potent than morphine, with a high degree of efficacy.”
TQ-1015 is being developed for the treatment of chronic cancer and non-cancer pain. It is a once-a-day sustained release opioid analgesic in a proprietary, abuse deterrent drug delivery system. It will compete in the same market segment as Purdue Pharma’s MS Contin, OxyContin and Palladone, and Janssen’s Duragesic.